Abstract: Two human endogenous retroviruses of the HERV-W family are proposed as multiple sclerosis (MS) co-factors: MS-associated retrovirus (MSRV) and ERVWE1, whose env proteins showed several potentially neuropathogenic features, in vitro and in animal models. Phase II clinical trials against HERV-Wenv are ongoing. HERV-W/MSRV was repeatedly found in MS patients, in striking parallel with MS stages, active/remission phases, and therapy outcome. The HERV-Wenv protein is highly expressed in active MS plaques. Early MSRV presence in spinal fluids predicted worst MS progression 10 years in advance. Effective anti-MS therapies strongly reduced MSRV/Syncytin-1/HERV-W expression. The Epstein-Barr virus (EBV) activates HERV-W/MSRV in vitro and in vivo, in patients with infectious mononucleosis and controls with high anti-EBNA1-IgG titers. Thus, the two main EBV/MS links (infectious mononucleosis and high anti-EBNA1-IgG titers) are paralleled by activation of HERV-W/MSRV. It is hypothesized that EBV may act as initial trigger of future MS, years later, by activating MSRV, which would act as direct neuropathogenic effector, before and during MS.
Introduction
Multiple sclerosis (MS) is a multifactorial disease. The immunopathogenic phenomena of MS are thought to be triggered by environmental (viral?) factors operating on a predisposing genetic background. Several viruses have been proposed as co-factors that may contribute to MS risk, either by infecting the brain, or activating peripheral, cross-reactive T-cells, acting against nerve myelin. 1 In most cases, the link with MS was weak.
The most consistent, and independently confirmed, studies exist for the Epstein-Barr virus (EBV), 2, 3 and for two members of the W family of human endogenous retroviruses (HERV): MS-associated retrovirus (MSRV) and ERVW-1, an element expressing only the env protein, named Syncytin-1, as reviewed in Dolei and colleagues. [4] [5] [6] In some way, the HERVs are intermediate between exogenous viruses and genes, as they are the remnants of ancient infections by regular retroviruses, endogenously transmitted through generations, for tens of millions of years; presently, they constitute ~8% of human DNA. The HERVs are poorly and variably expressed, being generally highly defective, but a handful of complete proviruses have been described, with the classical genome organization of a retrovirus, that is, two long terminal repeat regions (LTR), including the gag, pol, and env genes. 4, 6, 7 The most studied HERV is the HERV-W family, since the discovery of its founder member, MSRV, a complete virus with extracellular virions, 8 and the finding that the Syncytin-1 protein, which has pivotal physiological functions during early pregnancy, is the only product encoded by ERVWE1, a replication-incompetent HERV-W element, located on human chromosome 7q21-22. 9 As reviewed in Dolei and colleagues, 5, 10 MSRV might be either an exogenous HERV-W, or a non-ubiquitous replication-competent member, or a partly defective, non-ubiquitous copy, seldom complemented, or recombined within the HERV-W family. reviewed in some of the studies. 4, 7, 10, 11 Both env proteins have pro-inflammatory and superantigenic properties, and have been shown to cause neurotoxic effects in vitro and in humanized or transgenic animal models: 12,13 they may cause neuroinflammation, neurodegeneration, alterations of the immune system, and stress responses; both have been suggested as cofactors triggering the immuno-pathogenesis of MS.
The HERV-Ws, the herpesviruses, and the risk of MS As stated above, several viruses have been proposed as co-factors of MS, as reviewed in Cusick et al., 1 including members of the family of Herpesviridae, such as the human herpesvirus 6 (HHV-6), reviewed in Tao et al., 2 EBV, 2,3 and the already mentioned HERV-W/MSRV/Syncytin-1. [4] [5] [6] [7] 11, 14 As for HHV-6, meta-analyses provided some support for a link between HHV-6 and MS, but none showed causative relationships, and findings across the field are non-uniform. 2 The expression of both HERV-Ws and HHV-6 was evaluated within the same samples of brain and peripheral blood mononuclear cells (PBMC) of MS patients and controls, by detection of two different transcripts for each virus (MSRV/HERV-W env and pol, HHV-6 U94/rep, which maintains the latent state, and DNA-pol, indicative of actively replicating virus). The MSRV/HERV-W was found to be expressed actively in brains and in PBMC of MS patients, while there were no significant differences between these MS patients and controls for HHV-6 presence/replication at the brain or PBMC level. 15 More consistent studies for a potential virus involvement in MS exist for EBV, as reviewed in Tao et al. 2 and Fernández-Menéndez et al. 3 The risk of developing MS is higher among EBV-infected individuals, especially if the EBV infection occurs in late adolescence or adulthood, when the infection is symptomatic. A meta-analysis showed an association between the appearance of anti-EBV antibodies and the MS onset, 5-20 years later; another paper reported that the relative risk of MS for a past history of infectious mononucleosis is 2.17 and increases in persons with certain MHC haplotypes. 2, 3 The MS-EBV link remains unclear and seems to be indirect, since no studies have found evidence of EBV expression specific to MS, and currently there is no consensus in establishing whether there is a presence of EBVinfected cells in the central nervous system (CNS) of MS patients. Therefore, it remains to be determined whether EBV would continue to play a role after disease initiation. 2, 3 In search of links between EBV and HERV-W/MSRV/ Syncytin-1, the expression of HERV-W/MSRV/ Syncytin-1 was studied in vitro, with/without exposure to EBVgp350 (the major protein of EBV envelope), on PBMC from healthy donors and MS patients, and on astrocytes, 5 and, in another study, in hospitalized young adults with infectious mononucleosis, and healthy controls, who were either EBV-negative or latently EBVinfected, with/without high titers of anti-EBNA-1 IgG. 16 The results showed that in vitro EBV activates the potentially immunopathogenic and neuropathogenic HERV-W/MSRV/Syncytin-1, in cells deriving from blood and brain. In vivo HERV-W/MSRV activation was higher in blood cells of patients with infectious mononucleosis, and in healthy controls with high anti-EBNA-1 IgG titers. Thus, the conclusion was that the two main links between EBV and MS (infectious mononucleosis and high anti-EBNA-1-IgG titers) are paralleled by activation of the potentially neuropathogenic HERV-W/MSRV. Therefore, it was postulated the possibility for EBV of an initial trigger of future MS, years later, and for MSRV of a direct role of effector of neuropathogenesis, before and during MS. 5, 16 HERV-W/MSRV/Syncytin-1 expression in culture Cultured human astrocytes express HERV-W/MSRV/ Syncytin-1, which can be modulated in response to viral and inflammatory stimuli. 5, 17, 18 In cultured PBMC from MSRV-positive individuals, 5, 19 MSRV release was upregulated by pro-inflammatory cytokines, such as TNFα, IL-6, and interferon γ (while inhibited by the beneficial interferon β). These proinflammatory cytokines, in turn, are overproduced in response to MSRV/HERV-Wenv by cells from MS patients, and correlate with MS severity, 20 thus providing a pathogenic amplification loop.
Animal models
In the brain of mice implanted with a Syncytin-1 construct, oligodendrocytes were found sensitive to Syncytin-1-mediated release of redox reactants from astrocytes, 13 and MSRV particles caused T-celldependent death in humanized severe combined immunodeficient (SCID) mice. 12 MSRVenv alone was shown to promote experimental allergic encephalomyelitis (EAE) in mice, that is, the animal model of human MS. 21 If the mice with full-blown EAE were treated with an anti-HERV-Wenv protein monoclonal antibody, a reversal of clinical score kinetics toward healing was observed, while all untreated animals died (or had to be euthanized because of complete paralysis). 22 
HERV-W/MSRVW/Syncytin-1 expression in vivo
Whatever the origin of MSRV is, a meta-analysis revealed that ~9% of healthy Caucasian blood donors have MSRV viremia, as detected by reverse transcription polymerase chain reaction (RT-PCR), 10 and viremia increases during inflammatory diseases. 14, 23, 24 Expression of HERV-W/ MSRV/Syncytin-1 occurs at the RNA and protein level in circulating monocytes, NK, and B cells, but not in T-cells, and the expression increases during monocyte differentiation into macrophage. 5 Optic neuritis is a disease frequently prodromic to MS: in the blood and in the spinal fluid of these patients, MSRV positivity was significantly higher than in pathological controls, and the conversion to full-blown MS in the next 20 months occurred only among those patients who had already MSRV-positive spinal fluids, 25 as reported on Figure 1(a) .
As for MS patients, to date, the presence of extracellular MSRV particles and the expression of MSRVenv and Syncytin-1 transcripts/proteins have been detected independently by several groups, in the blood and the brain, and found increased with respect to both healthy and pathological controls, as reviewed in some of the studies. 4, 7, 10, 11 This has been confirmed by a meta-analysis of 43 reports. 29 MSRV blood positivity ranged from 50% to 100% of MS patients. 11 A multicentre study found MSRV positivity of MS patients proportionate to local MS prevalence: Spain (low MS): 59%, Sweden (high MS): 73%; Sardinia, Italy (highest prevalence worldwide): 100%. 14 MSRV positivity increased in the relapses, 6 as well as with MS duration and progression, from onset up to secondary progressive MS (SPMS). 23, 24, 25, 29, 30 MSRV positivity of spinal fluids increased with MS duration, 23 and MS phase, 26 and its presence in early MS was related to worse prognosis in the next 10 years, as reported in a blind follow up of patients close to MS onset, starting in comparable conditions (but differing in MSRV positivity of the spinal fluids). The study showed that early MSRV presence in spinal fluids was associated with a significantly greater rate of disability and disease progression, detectable after 3, 31 6, 32 and 10 years. 26 Of note, the progression to SPMS occurred only among the patients who at start had MSRV-positive spinal fluids, as reported on Figure 1(b) . 26 The authors proposed MSRV evaluation as a prognostic marker for the individual patient, to monitor disease progression.
By discriminatory PCR assays, that amplify selectively either MSRVenv or Syncytin-1, the DNA of MS patients was found to have on average six-fold more MSRVenv copies than controls (p = 0.02), while the Syncytin-1 copies were almost identical for both patients and controls. 33 A subsequent study found a statistically significant 19% increase in MSRVenv DNA copies, influenced by gender and disease severity. 30 25 (b) Progression to the secondary progressive (SPMS) course within 10 years of early RRMS patients, according to presence/absence of HERV-W/MSRV genomic RNA in the spinal fluids at study entry; for details, see Sotgiu et al. 26 (c) Circulating HERV-W/MSRV and disease outcome of MS patients, after 12 months of efficacious therapy with interferon β or natalizumab. To compare the two studies, 27, 28 the original data were normalized to the mean HERV-W/MSRV RNA values at study entry, taken as 100%. In the interferon β study, 27 virionic HERV-W/ MSRVenv RNA was evaluated, by real-time quantitative RT-PCR amplification, and post-therapy levels were below detection limits of the assay (<10 copies/reaction). In the natalizumab study, 28 HERV-W/MSRVenv mRNA was evaluated, by real-time semi-quantitative RT-PCR amplification. Bars indicate standard deviation.
In the brain, expression of HERV-Wenv occurs essentially in MS lesions, in astrocytes, as well as in macrophages, endothelial, and microglial cells, linked to the extent of active demyelination and inflammation. 7, 13, 15, 34 HERV-W/MSRV/Syncytin-1 expression during MS therapy When MS patients undergo successful therapies, the expression of MSRV diminishes accordingly. In a longitudinal evaluation of MS patients, during efficacious therapy with interferon β, it was found that MSRV viremia fell rapidly below detection limits (the earliest effect was detected 48 hours after the first drug shot; 27 notably, a patient, after initial clinical and virological benefit, had MSRV rescue, preceding a strong disease progression and therapy failure. The effects of interferon β therapy on MSRV were confirmed by an independent follow-up study, which observed significant decreases in anti-HERV-Wenv and anti-HERV-Henv antibody reactivity after interferon β therapy, closely linked to efficacy of therapy and low disease activity, as detected by time-resolved immunofluorometric assay (TRIFMA) for anti-env peptide antibodies. 35 Also, the therapy with natalizumab was shown in a longitudinal study to reduce strongly HERV-W/MSRV/Syncytin-1 expression, in parallel with the clinical benefit of the therapy for the patients, as detected by flow cytometry and by discriminatory env-specific RT-PCR assays, at the protein and RNA levels, respectively. 28 In all cases, when HERV-W/MSRV/Syncytin expression was measured in MS patients under therapy, it was found reduced accordingly. In Figure 1(c) , the percent reduction in MSRV expression in MS patients under therapy with interferon β and natalizumab is reported. Also MS patients under fingolimod (data from author's group, to be published elsewhere), and under azathioprine or glatiramer acetate, have been tested for HERV-Wenv expression, which was found reduced with respect to untreated patients, as detected by flow cytometry and by discriminatory env-specific RT-PCR assays, at the protein and RNA levels, respectively. 5 The mean reduction in MSRV RNA expression in the above studies ranged from 4 to ~1 Log 10 , with respect to study entry (in longitudinal studies) or to untreated control MS patients (in horizontal studies).
Clinical trials
In view of the above findings, attempts to target the neuropathogenic HERV-Wenv protein in MS patients were undertaken. A phase 2a clinical study showed safety of the treatment with an anti-HERV-Wenv protein, 22 and further phase 2b clinical trial studies from the same group are running, while this paper is written.
Concluding remarks
A significant part of our DNA is constituted by HERVs, which passed successfully 10-60 million years in the genomes of our ancestors. Mutual adaptations occurred, and in some cases, the host turned to his advantage some of these foreign genomes, to serve physiological functions, as for HERV-W/Syncytin-1, mediator of the formation of the syncytiotrophoblast layer during early pregnancy. Over time, some retroelements originated positive genetic variability, but also inheritable or inducible diseases. The HERVWenv protein was shown to have immunopathogenic and neuropathogenic effects in vitro and in animal models. Since MSRV discovery in patients affected by MS, several groups, including the author, have confirmed independently the links between HERV-W and MS.
Over time, the group of the author found that MSRV expression parallels MS onset, behavior, and therapy outcome. In vivo MSRV in the spinal fluid of patients with optic neuritis is predictive of conversion to MS; MSRV in the spinal fluid of patients at MS onset is predictive of worst prognosis and to progression to the secondary progressive phase in the next 10 years. The genome of MS patients has more MSRV DNA copies than controls. HERV-W/MSRV can be considered a biomarker for MS behavior and therapy outcome. In vitro, the expression of HERV-W/MSRV/ Syncytin-1 in blood cells and astrocytes is upregulated by pro-inflammatory cytokines and inhibited by interferon α and interferon β. This confirms that both MSRV and Syncytin-1 can be activated in an inflammatory environment, as observed in vivo in MS, and it suggests that the neurotoxic and immune-related properties of HERV-Wenv could contribute to the pathogenesis of MS. This possibility is reinforced by the findings that EBV activates the HERV-W/MSRV/ Syncytin-1, in cells deriving from blood and brain in vitro, and that in vivo HERV-W/MSRV is activated in patients with infectious mononucleosis, and in healthy controls with high anti-EBNA-1 IgG titers. This indicates that the two main links between EBV and MS (infectious mononucleosis and high anti-EBNA-1-IgG titers) are paralleled by activation of the potentially neuropathogenic HERV-W/MSRV. Therefore, we postulated for EBV the role of initial trigger of future MS, years later, by activating HERV-W/MSRV, which would act as a direct contributor to neuropathogenesis, before and during MS. Moreover, HERV-W/ MSRV could be the common link between various triggering co-factors and the immunopathogenic cascade leading to MS neurodegeneration. If so, this may open new avenues of intervention.
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